Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2021-09-03 00:00:00 ET · period of report 2021-09-01 · accession 0001209191-21-054888 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-03 | 2021-09-01 | TARS | Ackermann Michael | Dir | S - Sale | $25.24 | -5,833 | 1.22M | -0.5% | -$147.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-01 | S | D | 5,833 | $25.24 | 1,221,515 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.970, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |